

Da: GRA EU Italy <GRAEUItaly@viatris.com>

Inviato: martedì 20 ottobre 2026 16:43

Cc: Valeria Pascarelli <Valeria.Pascarelli@viatris.com>

Oggetto: Notifica Cessata commercializzazione Temporanea per Rosuvastatina Mylan e Definitiva per Amitriptilina Mylan

Spettabile Banca Dati,

la presente per informarVi che abbiamo comunicato la **Cessata commercializzazione temporanea** dei seguenti prodotti:

Descrizione	AIC/PARAF	Data di inizio cessata commercializzazione	Ultimo lotto	Scadenza lotto
Rosuvastatina Mylan 5mg compresse rivestite con film – 28 compresse in blister OPA/AL/PVC	042575631	20/10/2026	3258954	31.12.2027
Rosuvastatina Mylan 10mg compresse rivestite con film – 28 compresse in blister OPA/AL/PVC	042575720	20/10/2026	3257009	30.11.2027
Rosuvastatina Mylan 20mg compresse rivestite con film – 28 compresse in blister OPA/AL/PVC	042575819	20/10/2026	8215643	30.09.2027
Rosuvastatina Mylan 40mg compresse rivestite con film – 28 compresse in blister OPA/AL/PVC	042575908	20/10/2026	8212435	31.07.2027

Inoltre, si fa presente che la Società aveva già comunicato la situazione di carenza relativa alle referenze e per cui è stata modificata la carenza in cessata temporanea.

Per ultimo, abbiamo comunicato la **Cessata commercializzazione definitiva** della seguente AIC, come da tabella sotto:

Descrizione	AIC/PARAF	Data di inizio cessata commercializzazione	Ultimo lotto	Scadenza lotto
Amitriptilina Mylan 40mg/ml gocce orali soluzione – 1 flacone in vetro da 20ml	045418011	21/10/2026	260297	28.02.2029

Si resta a disposizione.

Cordialmente

Betiola Bulku

Regulatory Affairs Specialist

Regulatory Affairs Department

Viatrix Italia S.r.l.

Viale Piero e Alberto Pirelli, 10

20126 - Milano

betiola.bulku@viatris.com

Mobile: +39.3207671768

Viatris.com



This email message and any attachments are for the exclusive use of the intended addressee(s). This message may contain confidential, privileged and/or proprietary information, and unauthorized review, use or distribution by persons other than the intended addressee(s) is strictly prohibited and may be unlawful. Unintended transmission does not waive any privilege including attorney-client, attorney work product or claims to confidentiality. If you received this email in error or it was forwarded from recipients who received it in error, please contact me by return message and immediately destroy all electronic, paper and other versions of this message.

Viatriis, Inc. and its affiliates and subsidiaries process your personal data in order to interact with you in the context of our business activities. Depending on your location, you may have the right to access, delete, restrict, edit, move, or object to our use of your personal data. You may also have the right to report concerns to the authority responsible for data protection where you live or work. You can learn more about our data protection practices by accessing our Privacy Policy (<https://www.viatriis.com/en-us/privacy-policy>). By accessing this link, you can learn about the personal data we process, how it is shared, where it is stored, to where it may be transferred, for how long we keep it, and how to contact our Data Protection Officer. For questions or concerns related to data protection, please email dataprivacy@viatriis.com.



Please think before you
print.



[View in other languages.](#)